In a CML mouse model, inhibition of Dusp1 activated p38MAPK and sensitized BCR-ABL-positive CML stem cells to imatinib with complete clearance of minimal residual disease [68]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.